HOME >> MEDICINE >> NEWS
OHSU researchers discover possible HIV therapy in an animal study

ls when given in conjunction with antiretroviral drugs."

Antiretroviral drugs are currently given to HIV-positive patients and are shown to slow the proliferation of the HIV virus, allowing patients to live longer. This research clearly demonstrated the importance of retroviral drugs in allowing for restoration of T cell population. This was done by observing SIV-positive animals that received IL-15 without antiretroviral drugs. This group of animals did not demonstrate the same improvements in T cell levels witnessed in animals receiving both IL-15 and antiretroviral drugs.

"What we now need to better understand is how populations of these crucial T cells are regulated," explained Picker. "We're also hopeful that this research will lead to effective therapies for treating patients with HIV and boosting their immune systems, making them less susceptible."


'"/>

Contact: Jim Newman
newmanj@ohsu.edu
503-494-8231
Oregon Health & Science University
8-Jun-2006


Page: 1 2

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
3. Penn researchers discover novel pathway for increasing good cholesterol
4. Theory of facial aging gets a facelift from UT Southwestern researchers
5. UIC researchers to develop new drugs to fight bioterrorism
6. UQ researchers discover some of the oldest forms of life
7. U of M researchers discover new method to combat HIV
8. U of M researchers assess effectiveness of computerized physician order entry system
9. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
10. Physician-researchers often less successful in obtaining NIH funding
11. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OHSU researchers discover possible HIV therapy animal study

(Date:5/21/2013)... Long Beach, CA (PRWEB) May 21, 2013 ... the 3rd Annual EB-5 Investment Summit: Dealmakers Conference ... The Dealmakers Conference will focus on exploring alternative ... will provide the latest market, legal and economic ... executives, immigration and legal professionals within the EB-5 ...
(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... on cable networks and cable channels across the country, ... on its YouTube channel. The producers of the series ... in the shipping industry, the manufacturing industry, health-related companies, ... medical facilities and medical practitioners in all parts of ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
(Date:5/21/2013)... , May 21, 2013   Accuray ... today the publication of study results involving hundreds ... Robotic Radiosurgery System, the most widely used form ... study followed 304 patients for a median of ... and found that 97 percent of patients with ...
(Date:5/21/2013)... CITY, Calif. , May 21, 2013 ... point-of-care blood analysis systems, announced today that ... present at the Stifel Annual Dental & Veterinary Conference ... The conference will be held at Le Parker Meridien ... About Abaxis Abaxis develops, manufactures, ...
(Date:5/21/2013)... , May 21, 2013 Ceregene, Inc. ... analysis of its double-blind, randomized, controlled Phase 2b ... gene therapy product designed to deliver the neurotrophic ... identified a more robust response to CERE-120 in ... treatment relative to those diagnosed 10 years or ...
Breaking Medicine Technology:New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 2New Data Validates CyberKnife SBRT for Prostate Cancer Treatment 3Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 2Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 3Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 4Ceregene Reports Additional Efficacy Data From Parkinson's Disease Phase 2b Study 5
Cached News: